Navigation Links
MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
Date:5/30/2008

Results presented at major U.S. cancer conference

CHICAGO, May 30 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's (ASCO) annual meeting. Collectively, these findings show that MammaPrint, a prognostic test for breast cancer recurrence using a 70-gene signature, provides important information for more effective patient management.

"These studies demonstrate the clinical utility of MammaPrint in helping physicians make more informed decisions about the course of care for their patients with breast cancer," said Laura van 't Veer, Ph.D., Head of Molecular Pathology at the Netherlands Cancer Institute in Amsterdam, who participated in both studies. "Prognostic tests such as MammaPrint have ushered in a new era in personalized medicine, helping us to determine the most appropriate care based on an individual patient's risk and treatment preferences. This might mean, in some cases, avoiding harsh therapies that may otherwise not be effective."

In the first study (abstract #527), conducted at The University of Texas M.D. Anderson Cancer Center in Houston, tumor samples from 198 patients with early stage, lymph-node negative breast cancer were analyzed with multiple gene-expression assays, including MammaPrint, to determine whether both prognostic and treatment prediction data could be generated from a single specimen.

Among 32% of patients (64 of 198) predicted to be at low risk for breast cancer recurrence with MammaPrint, 31% (20 of 64) were predicted to be highly sensitive to endocrine therapy while 88% (56 of 64) were predicted to be insensitive to chemotherapy. The remaining 134 patients who were considered to be at high risk for cancer recurrence, were predominantly predicted chemo-sensitive (>51%). The abstract
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
4. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
5. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
11. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)... iSirona Appoints John Cooper as Chair... City, Fla. (PRWEB) November 10, 2009 -- iSirona&r...utions for healthcare providers, today announced t...oard, effective October 21, 2009. He replaces Chai...nue to serve as the company,s CEO and retains a se...
(Date:11/9/2009)...JING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Yongye... "the Company") a leading manufacturer, developer,...mal nutrient products in the,People,s Republic of ...a,conference call at 10:00 a.m. Eastern Time (11:0...to discuss results for the quarter ended September...
(Date:11/9/2009)... Va., Nov. 9 CEL-SCI Cor...r. Kenneth S. Rosenthal, Professor of Immunology a...College of Medicine and Pharmacy, reported on work... Cleveland Clinic and CEL-SCI on CEL-SCI,s LEAPS v...7th GTCbio Vaccine: "All Things Considered" Confer...
(Date:11/8/2009)...TAIN VIEW, Calif. Nov. 5, 2009 Complete Genomics...ny, today announced publication of a report in the...sequencing platform, including analysis of sequenc...umables cost for these three genomes sequenced on ...ed from $8,005 for 87x coverage to $1,726 for 45x ...
Breaking Biology Technology:iSirona Selects New Chairman of the Board 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2
... non-mechanical heart valve businesses expected to...over-year, MINNEAPOLIS, April 3, 2008 ATS Medica...r of state-of-the-art cardiac,surgery products and...lts,for the first quarter of 2008., (Logo: http:..., The Company currently expects revenue for the f...
...the key engineering challenges to building a clean... the fuel tank. Storing enough raw hydrogen for a ...actically high pressures for gaseous hydrogen or e...a new paper* researchers at the National Institute...esearch (NCNR) have demonstrated that a novel clas...
...ril 2, 2008 With their ability to extend,product ...as part of Big,Pharma,s strategy during lean times...rding to a new report from a major life sciences m...ipients on the market, used in all types,of pharma...healthy growth,in the past few years and is expect...
Other Biology Technology:ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 2ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 3More solid than solid: A potential hydrogen-storage compound 2Excipients Help Pharma Extend Product Life, Profits 2
(Date:11/9/2009)... wings has inspired a 3.2m, three-year research pr...ields of security, energy and the environment. The... company QinetiQ have just signed a collaborative ...ndbreaking physical sciences research. , Over t...University of Exeter and QinetiQ will work togethe...
(Date:11/9/2009)...09 A nutritionist whose research was instrumental...men, Infants and Children (WIC) food subsidy will ... outstanding achievement in the field of maternal-..., a professor in the Department of Community Healt...geles School of Public Health, will receive the aw...
(Date:11/6/2009)...rsary this month of the publication of On the Orig...l Sciences (AIBS) is publishing open access two pe...historic insights into evolution. , The two artic...ornia, Berkeley, and James T. Costa of Western Car...ut Charles Darwin," appeared in the October issue ...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 1Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 2Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 3Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 4Hospitals Reduce Heart Attack Deaths 54790 1Hospitals Reduce Heart Attack Deaths 54790 2Hospitals Reduce Heart Attack Deaths 54790 3Thra Wise All Natural Ointment Now Available at Shoppers Drug Mart 54787 1Thra Wise All Natural Ointment Now Available at Shoppers Drug Mart 54787 2Thra Wise All Natural Ointment Now Available at Shoppers Drug Mart 54787 3
...d by researchers at the University of California, ...lements can lower concentrations of C-reactive pro...at has been shown to be a powerful predictor of he...benefit from daily doses of vitamin E, another ant...rger, eight-year clinical trial led by researchers...
...es now allow scientists to monitor changes to wate...heets and even under the ground. As the climate ch...ring its effects and predicting future impacts in ... major consequences of global warming, but it is m...rature. It involves the oceans and their interacti...
...ilable in German , , Duisburg/Leipzig. In futur...er known as acrylic glass - could be made from nat...ty acids. PMMA is manufactured by polymerising met...entists at the University of Duisburg-Essen and th...) have found an enzyme which could be used for the...
Other Biology News:Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease 2Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease 3Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease 4Measuring water from space 2Measuring water from space 3Acrylic glass made of sugar 2Acrylic glass made of sugar 3
...a;-1, clone C464.6 GenBank Accession Number : NM_...isolated from membrane fractions of rabbit kidney ....4, 0.15M NaCl containing 0.05% sodium azide Quali... rat brain microsomal preparations Recognizes &alp...
Mouse Anti-Human PSGL-1 Monoclonal Antibody, Unconjugated, Clone 215 from Santa Cruz Biotechnology, Inc.
Mouse Anti-Adenovirus Type 7 hexon C11 Monoclonal Antibody, Unconjugated, Clone 1-N-14 from GeneTex
Mouse Anti-20S proteasome subunits alpha 1 Monoclonal Antibody, Unconjugated, Clone MCP231 from Upstate
Biology Products: